Takeshi Takahashi
Director/Board Member at Pathalys Pharma, Inc.
Profile
Takeshi Takahashi is currently the Director at Pathalys Pharma, Inc. He previously worked as an Independent Director at Mineralys Therapeutics, Inc. from 2020 to 2023.
He also held the position of Co-Chief Operating Officer & Manager-Technology II at Tsugami Corp.
Mr. Takahashi completed his undergraduate degree at Waseda University and holds an MBA from Kellogg School of Management.
Takeshi Takahashi active positions
| Companies | Position | Start |
|---|---|---|
Pathalys Pharma, Inc.
 Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Director/Board Member | - |
Former positions of Takeshi Takahashi
| Companies | Position | End |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Director/Board Member | 2023-09-11 |
| TSUGAMI CORPORATION | Chief Operating Officer | - |
Training of Takeshi Takahashi
| Waseda University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| TSUGAMI CORPORATION | Producer Manufacturing |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
- Stock Market
- Insiders
- Takeshi Takahashi
